Plevitrexed
Cat. No.：YN270263
| 产品名称: | Plevitrexed |
| CAS No.: | 153537-73-6 |
| Chemical Name: | (αS)-α-[[4-[[(1,4-Dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl]-2-propynylamino]-2-fluorobenzoyl]amino]-1H-tetrazole-5-butanoic Acid; BGC 9331; NSC 696259; ZD 9331; Vamidex; |
| Synonyms: | ZD 9331; BGC9331 |
| 分子量: | 532.53 |
| 分子式: | C₂₆H₂₅FN₈O₄ |
| SMILES: | O=C(NC(C)=N1)C2=C1C=C(C)C(CN(C3=CC=C(C(N[C@H](C(O)=O)CCC4=NNN=N4)=O)C(F)=C3)CC#C)=C2 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Plevitrexed (ZD 9331; BGC9331) 是口服有效的胸苷酸合酶 (TS) 抑制剂，Ki值为 0.44 nM。Plevitrexed 通过 α-叶酸受体以及还原的叶酸载体吸收。Plevitrexed 有用于胃癌的潜力。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Sirotnak, F., et al.: Cancer Res., 45, 3992 (1985), Touroutoglou, N., et al.: Clin. Cancer Res., 2, 227 (1996 ), Twelves, C., et al.: Clin. Cancer Res., 5, 1696 (1999), Goh, B., et al.: J. Clin. Oncol., 19, 1476 (2001),
